Cantor Fitzgerald Predicts Humana FY2026 Earnings

Humana Inc. (NYSE:HUM) – Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Humana in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst S. James forecasts that the insurance provider will post earnings of $14.58 per share for the year. Cantor Fitzgerald has a “Neutral” rating and a $290.00 price objective on the stock. The consensus estimate for Humana’s current full-year earnings is $16.47 per share.

Other research analysts also recently issued reports about the company. Wall Street Zen upgraded Humana from a “hold” rating to a “buy” rating in a research note on Friday, May 9th. Royal Bank of Canada reissued an “outperform” rating and issued a $283.00 price target on shares of Humana in a report on Wednesday, February 12th. JPMorgan Chase & Co. cut their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th. Mizuho increased their price objective on shares of Humana from $305.00 to $316.00 and gave the company an “outperform” rating in a research report on Wednesday, April 9th. Finally, Morgan Stanley dropped their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Sixteen analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $284.48.

Humana Price Performance

Shares of HUM opened at $233.04 on Tuesday. The company has a 50 day moving average of $252.85 and a two-hundred day moving average of $264.23. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana has a twelve month low of $212.45 and a twelve month high of $406.46. The company has a market cap of $28.13 billion, a price-to-earnings ratio of 23.42, a price-to-earnings-growth ratio of 2.05 and a beta of 0.43.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.07 by $1.51. The business had revenue of $32.11 billion for the quarter, compared to analysts’ expectations of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. The company’s revenue was up 8.4% compared to the same quarter last year. During the same period last year, the business earned $7.23 EPS.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a dividend yield of 1.52%. Humana’s dividend payout ratio (DPR) is presently 25.04%.

Institutional Trading of Humana

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Humana by 8.9% during the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock valued at $3,697,222,000 after acquiring an additional 1,143,662 shares in the last quarter. Dodge & Cox increased its holdings in Humana by 5.5% in the first quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider’s stock valued at $2,845,830,000 after buying an additional 557,175 shares in the last quarter. Pzena Investment Management LLC raised its position in shares of Humana by 6.1% in the first quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider’s stock worth $1,013,133,000 after acquiring an additional 219,541 shares during the period. Geode Capital Management LLC grew its position in shares of Humana by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider’s stock valued at $729,658,000 after acquiring an additional 63,562 shares during the period. Finally, Invesco Ltd. increased its stake in shares of Humana by 29.8% in the 4th quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider’s stock valued at $608,348,000 after purchasing an additional 550,692 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.